Melinda L Telli MD

Oncology•Stanford, CA

Breast Cancer

Associate Professor of Medicine - Oncology, Stanford University Medical Center

Join to View Full Profile

300 Pasteur DrStanford, CA 94305
Phone+1 650-723-4000
Fax+1 650-723-0074

Education & Training

Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 2002 - 2005
George Washington University School of Medicine and Health SciencesClass of 2002

Certifications & Licensure

CA State Medical License 2003 - 2025
FL State Medical License 2020 - 2022
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women Start of enrollment: 2000 Oct 01
Completed
Phase 2
Development of Vitamin D as a Therapy for Breast Cancer - Phase 2 Start of enrollment: 2008 Apr 01
Completed
Phase 2
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
Vitamin D and Breast Cancer: Does Weight Make a Difference? Start of enrollment: 2011 Nov 01
Terminated
Phase 2
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer Start of enrollment: 2012 Jun 13
Completed
Phase 2
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer Start of enrollment: 2012 Aug 01
Completed
Phase 2
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI Start of enrollment: 2013 May 31
Completed
Phase 2
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors Start of enrollment: 2014 Feb 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

3 citations
Pembrolizumab and chemotherapy in high-risk, early-stage, ER/HER2breast cancer: a randomized phase 3 trial.
Fatima Cardoso, Joyce O'Shaughnessy, Zhenzhen Liu, Heather McArthur, Peter Schmid
Nature Medicine. 2025-02-01
VISTA-induced tumor suppression by a four amino acid intracellular motif.
Yan Zhao, Tina Andoh, Fatima Charles, Priyanka Reddy, Kristina Paul
Biorxiv. 2025-01-05
7 citations
Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status.
Melinda L Telli, Jennifer K Litton, J Thaddeus Beck, Jason M Jones, Jay Andersen
Breast Cancer. 2024-09-01

Lectures

Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in ear...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

NCCN: Updated Guidelines Reflect Advances, ‘Immunotherapy Era’ for Breast CancerApril 15th, 2019
Technique Could Help Identify Patients Who Would Suffer Chemo-Induced Heart DamageApril 18th, 2016
Anthracycline-Free Neoadjuvant Regimen Safe, Effective for TNBCMarch 6th, 2021
Join now to see all

Professional Memberships